ArticleJournal for immunotherapy of cancer2025
Author response to comment on "Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer".
Hyung-Don Kim et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.